127 related articles for article (PubMed ID: 35059847)
1. Who should be treated with pembrolizumab in addition to standard of care in advanced cervical cancer?
Kahraman S; Erbas UE; Yalcin B
Med Oncol; 2022 Jan; 39(3):33. PubMed ID: 35059847
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Sun JM; Shen L; Shah MA; Enzinger P; Adenis A; Doi T; Kojima T; Metges JP; Li Z; Kim SB; Cho BC; Mansoor W; Li SH; Sunpaweravong P; Maqueda MA; Goekkurt E; Hara H; Antunes L; Fountzilas C; Tsuji A; Oliden VC; Liu Q; Shah S; Bhagia P; Kato K;
Lancet; 2021 Aug; 398(10302):759-771. PubMed ID: 34454674
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
Winer EP; Lipatov O; Im SA; Goncalves A; Muñoz-Couselo E; Lee KS; Schmid P; Tamura K; Testa L; Witzel I; Ohtani S; Turner N; Zambelli S; Harbeck N; Andre F; Dent R; Zhou X; Karantza V; Mejia J; Cortes J;
Lancet Oncol; 2021 Apr; 22(4):499-511. PubMed ID: 33676601
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Basté N; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Wan Ishak WZ; Hong RL; González Mendoza R; Roy A; Zhang Y; Gumuscu B; Cheng JD; Jin F; Rischin D;
Lancet; 2019 Nov; 394(10212):1915-1928. PubMed ID: 31679945
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer.
Shi Y; Chen J; Shi B; Liu A
Gynecol Oncol; 2022 Feb; 164(2):379-385. PubMed ID: 34920886
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer.
McNamara B; Chang Y; Mutlu L; Harold J; Santin AD
Expert Opin Biol Ther; 2023 Mar; 23(3):227-233. PubMed ID: 36800548
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.
Chung HC; Ros W; Delord JP; Perets R; Italiano A; Shapira-Frommer R; Manzuk L; Piha-Paul SA; Xu L; Zeigenfuss S; Pruitt SK; Leary A
J Clin Oncol; 2019 Jun; 37(17):1470-1478. PubMed ID: 30943124
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Gallacher D; Armoiry X; Auguste P; Court R; Mantopoulos T; Patterson J; De Santis M; Cresswell J; Mistry H
Pharmacoeconomics; 2019 Jan; 37(1):19-27. PubMed ID: 30030817
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.
Nosaki K; Saka H; Hosomi Y; Baas P; de Castro G; Reck M; Wu YL; Brahmer JR; Felip E; Sawada T; Noguchi K; Han SR; Piperdi B; Kush DA; Lopes G
Lung Cancer; 2019 Sep; 135():188-195. PubMed ID: 31446994
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.
Shitara K; Van Cutsem E; Bang YJ; Fuchs C; Wyrwicz L; Lee KW; Kudaba I; Garrido M; Chung HC; Lee J; Castro HR; Mansoor W; Braghiroli MI; Karaseva N; Caglevic C; Villanueva L; Goekkurt E; Satake H; Enzinger P; Alsina M; Benson A; Chao J; Ko AH; Wainberg ZA; Kher U; Shah S; Kang SP; Tabernero J
JAMA Oncol; 2020 Oct; 6(10):1571-1580. PubMed ID: 32880601
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab alone or with chemotherapy for squamous cell carcinoma of the head and neck: A cost-effectiveness analysis from Chinese perspective.
Zhou K; Li Y; Liao W; Zhang M; Bai L; Li Q
Oral Oncol; 2020 Aug; 107():104754. PubMed ID: 32428689
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab for advanced cervical cancer: safety and efficacy.
De Felice F; Giudice E; Bolomini G; Distefano MG; Scambia G; Fagotti A; Marchetti C
Expert Rev Anticancer Ther; 2021 Feb; 21(2):221-228. PubMed ID: 33183120
[No Abstract] [Full Text] [Related]
15. Pembrolizumab for the treatment of cervical cancer.
Marret G; Borcoman E; Le Tourneau C
Expert Opin Biol Ther; 2019 Sep; 19(9):871-877. PubMed ID: 31322926
[No Abstract] [Full Text] [Related]
16. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.
Shitara K; Özgüroğlu M; Bang YJ; Di Bartolomeo M; Mandalà M; Ryu MH; Fornaro L; Olesiński T; Caglevic C; Chung HC; Muro K; Goekkurt E; Mansoor W; McDermott RS; Shacham-Shmueli E; Chen X; Mayo C; Kang SP; Ohtsu A; Fuchs CS;
Lancet; 2018 Jul; 392(10142):123-133. PubMed ID: 29880231
[TBL] [Abstract][Full Text] [Related]
18. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
Balar AV; Castellano D; O'Donnell PH; Grivas P; Vuky J; Powles T; Plimack ER; Hahn NM; de Wit R; Pang L; Savage MJ; Perini RF; Keefe SM; Bajorin D; Bellmunt J
Lancet Oncol; 2017 Nov; 18(11):1483-1492. PubMed ID: 28967485
[TBL] [Abstract][Full Text] [Related]
19. Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study.
Wu YL; Zhang L; Fan Y; Zhou J; Zhang L; Zhou Q; Li W; Hu C; Chen G; Zhang X; Zhou C; Dang T; Sadowski S; Kush DA; Zhou Y; Li B; Mok T
Int J Cancer; 2021 May; 148(9):2313-2320. PubMed ID: 33231285
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10.
Wainberg ZA; Fuchs CS; Tabernero J; Shitara K; Muro K; Van Cutsem E; Bang YJ; Chung HC; Yamaguchi K; Varga E; Chen JS; Hochhauser D; Thuss-Patience P; Al-Batran SE; Garrido M; Kher U; Shih CS; Shah S; Bhagia P; Chao J
Clin Cancer Res; 2021 Apr; 27(7):1923-1931. PubMed ID: 33446564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]